SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Expanding Defensive Growth Index into Europe
ACL
|
|
|
+41.41%
in
395 days
<> 
<> The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada.
Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie...
|
Excellent play on baby boomers getting older
ACL
|
|
|
+4.75%
in
944 days
Alcon is the dominant player in the opthalmic market including drugs, devices, and over the counter eyecare products. As the boomers get older, they'll start going blind.
They also can benefit from the emerging markets getting wealthier so that their people with bad eyesight can start affording these treatments.
|
Mid-day Watch List: BA, ACL
ACL
|
|
|
+1.91%
in
6 days
(closed on 03/29/07)
Two possible TRIX plays for Monday (may wanna pick up this afternoon) BA Should flip on Monday. Near 52 week highs. Nice. ACL Flipping as we speak.
|
Alcon (ACL)
ACL
|
|
|
+12.81%
in
1010 days
I was looking through the list of top % gainers on the NYSE this evening and came across Alcon, ACL, which closed at $129.77, up $9.02 or 7.47% on the day. I do not own any shares of Alcon, but my son does own 5 shares in an account that I monitor. I believe this company deserves a spot on my blog so let me go over a few of the points that I think justifies its inclusion here....
...Taking into consideration my son's small investment in this stock, I have a small bias towards the stock. However, seriously, the stock traded nicely today in an otherwise weak market. The latest quarterly r...
|
From the Blogosphere
Big Pharma & Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma & Biotech – Zacks Analyst Interviews
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead Sciences, Biogen Idec and Acorda Therapeutics – Press Releases
|
|
|
For Immediate Release Chicago, IL – November 10, 2009 – Zacks.com announces the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech sector, including Alcon (ACL), Novartis (NVS), Gilead Sciences (GILD), Biogen Idec (BIIB) and Acorda Therapeutics (ACOR). A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/27081/Big+Pharma+and+Biotech.<>In the pharma space, we are positive on stocks like Alcon (ACL) and Novartis (NVS). We believe these companies will continue witnessing revenue grow...
|
Big Pharma and Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Alcon Delivers, Moves Ever Closer to $181
Back in August, I advised investors to load up on Alcon (ACL), the eye care company because, this New Year's, Novartis (NVS) could be forced to buy all of Nestle's (NSRGY.PK) approximately 150 million at a $181 price.
In brief, Nestle's has the right as of January 1 to sell all of its 52% share of Alcon to Novartis for 20.5% above the average of the past week price to a maximum of $181. I speculated that minority shareholders could piggyback on the ride to $181.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
More Resources
|
About Alcon Inc.
- Answers.com
